Xuanzhu Biopharmaceutical Co., Ltd. (HKG:2575)
Hong Kong
· Delayed Price · Currency is HKD 24.00
-0.60 (-2.44%)
Apr 29, 2026, 4:08 PM HKT
Xuanzhu Biopharmaceutical Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 652.23 | 135.25 | 142.89 | 1,125 | 625.5 | Upgrade
|
| Short-Term Investments | - | 0.19 | 0.07 | - | - | Upgrade
|
| Trading Asset Securities | - | 110.58 | 306.83 | 108.11 | 332.53 | Upgrade
|
| Cash & Short-Term Investments | 652.23 | 246.02 | 449.8 | 1,233 | 958.02 | Upgrade
|
| Cash Growth | 165.12% | -45.30% | -63.53% | 28.74% | 680.10% | Upgrade
|
| Accounts Receivable | 16.04 | 0.19 | - | - | - | Upgrade
|
| Other Receivables | - | 13.5 | 13.53 | 0.92 | 0.73 | Upgrade
|
| Receivables | 16.04 | 13.69 | 13.53 | 0.95 | 5.81 | Upgrade
|
| Inventory | 86.52 | 57.19 | 62.32 | 50.94 | 30.36 | Upgrade
|
| Other Current Assets | 77.62 | 52.1 | 16.79 | 31.23 | 10.83 | Upgrade
|
| Total Current Assets | 832.41 | 369 | 542.44 | 1,316 | 1,005 | Upgrade
|
| Property, Plant & Equipment | 115.73 | 172.15 | 197.43 | 153.97 | 127.07 | Upgrade
|
| Other Intangible Assets | 337.27 | 66.86 | 74.32 | 71.27 | 42.69 | Upgrade
|
| Long-Term Deferred Charges | 320.65 | 543.7 | 459.48 | 270.12 | 217.22 | Upgrade
|
| Other Long-Term Assets | 34.29 | 44.9 | 47.34 | 60.12 | 27.46 | Upgrade
|
| Total Assets | 1,640 | 1,197 | 1,321 | 1,872 | 1,419 | Upgrade
|
| Accounts Payable | 113.57 | 98.89 | 69.21 | 17.25 | 17.46 | Upgrade
|
| Accrued Expenses | 32.55 | 16.59 | 20.24 | 35.61 | 21.56 | Upgrade
|
| Current Portion of Leases | 0.65 | 0.83 | 5.15 | - | - | Upgrade
|
| Current Income Taxes Payable | 4.53 | - | - | 0 | 0.03 | Upgrade
|
| Current Unearned Revenue | 18.44 | 19.17 | 7.25 | - | - | Upgrade
|
| Other Current Liabilities | 52.05 | 43.79 | 41.27 | 9 | 28.18 | Upgrade
|
| Total Current Liabilities | 221.79 | 179.26 | 143.13 | 61.86 | 67.24 | Upgrade
|
| Long-Term Leases | - | 0.65 | 11.92 | 29.36 | 0.04 | Upgrade
|
| Long-Term Unearned Revenue | 34.99 | 41.63 | 55.72 | - | - | Upgrade
|
| Other Long-Term Liabilities | 13.31 | 18.37 | - | - | - | Upgrade
|
| Total Liabilities | 270.09 | 239.91 | 210.76 | 91.22 | 67.28 | Upgrade
|
| Common Stock | 517.95 | 450.61 | 450.61 | 450.61 | 1,413 | Upgrade
|
| Additional Paid-In Capital | - | 1,890 | 1,890 | 2,041 | 664.58 | Upgrade
|
| Retained Earnings | - | -2,081 | -1,524 | -711.3 | -725.25 | Upgrade
|
| Comprehensive Income & Other | 852.31 | 696.58 | 293.69 | - | 0 | Upgrade
|
| Shareholders' Equity | 1,370 | 956.71 | 1,110 | 1,781 | 1,352 | Upgrade
|
| Total Liabilities & Equity | 1,640 | 1,197 | 1,321 | 1,872 | 1,419 | Upgrade
|
| Total Debt | 0.65 | 1.48 | 17.07 | 29.36 | 0.04 | Upgrade
|
| Net Cash (Debt) | 651.59 | 244.54 | 432.73 | 1,204 | 957.98 | Upgrade
|
| Net Cash Growth | 166.45% | -43.49% | -64.06% | 25.68% | 746.80% | Upgrade
|
| Net Cash Per Share | 1.40 | 0.54 | 0.96 | 3.05 | - | Upgrade
|
| Filing Date Shares Outstanding | 517.95 | 450.61 | 450.61 | 450.61 | - | Upgrade
|
| Total Common Shares Outstanding | 517.95 | 450.61 | 450.61 | 450.61 | - | Upgrade
|
| Working Capital | 610.62 | 189.74 | 399.31 | 1,255 | 937.79 | Upgrade
|
| Book Value Per Share | 2.65 | 2.12 | 2.46 | 3.95 | - | Upgrade
|
| Tangible Book Value | 1,033 | 889.85 | 1,036 | 1,709 | 1,310 | Upgrade
|
| Tangible Book Value Per Share | 1.99 | 1.97 | 2.30 | 3.79 | - | Upgrade
|
| Buildings | - | 123.67 | 114.45 | 114.92 | 113.69 | Upgrade
|
| Machinery | - | 126.8 | 126.47 | 85.5 | 77.8 | Upgrade
|
| Construction In Progress | - | 1.79 | 1.64 | - | - | Upgrade
|
| Leasehold Improvements | - | 3.66 | 3.66 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.